Evidence map›Paper›PMID 41104039›Full record

ArticleNeuro-oncology advances

Label-free fluorescence lifetime imaging for real-time guidance of stereotactic biopsy: A feasibility study in brain cancer patients.

Alba Alfonso-Garcia, Julien Bec, Mohamed Abul Hassan, Silvia Noble Anbunesan, Lisanne Kraft, Matthew Bobinski, Lee-Way Jin, Han Sung Lee, Griffith R Harsh, Orin Bloch and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alba Alfonso-GarciaBiomedical Engineering Department, University of California, Davis, California, USA.
Julien BecBiomedical Engineering Department, University of California, Davis, California, USA.
Mohamed Abul HassanBiomedical Engineering Department, University of California, Davis, California, USA.
Silvia Noble AnbunesanBiomedical Engineering Department, University of California, Davis, California, USA.
Lisanne KraftBiomedical Engineering Department, University of California, Davis, California, USA.
Matthew BobinskiDepartment of Radiology, University of California, Davis, California, USA.
Lee-Way JinDepartment of Pathology and Laboratory Medicine, University of California, Davis, California, USA.
Han Sung LeeDepartment of Pathology and Laboratory Medicine, University of California, Davis, California, USA.
Griffith R HarshDepartment of Neurological Surgery, University of California, Davis, California, USA.
Orin BlochDepartment of Neurological Surgery, University of California, Davis, California, USA.
Laura MarcuBiomedical Engineering Department, University of California, Davis, California, USA.ORCID https://orcid.org/0000-0003-2369-0748

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
TRD3: Data Analytics and Intelligent Systems (AI-ML-DL-Visualization)P41EB032840 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Griffith R. Harsh · 2022 to 2026
$6.7M
Label-free fluorescence lifetime imaging for intraoperative real-time guidance of neurological proceduresR01CA250512 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Orin Bloch, Laura Marcu · 2021 to 2026
$3.0M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA250512NIBIB NIH HHS P41 EB032840
6 · The paper itself

Abstract

Background: Stereotactic needle biopsy is frequently indicated for the diagnosis of malignant gliomas in initial management and at tumor recurrence. Current techniques have a sampling error of 24% and diagnostic errors of 10%-30%. Fluorescence lifetime imaging (FLIm) distinguishes among types of brain tissue according to their intrinsic fluorescence properties. Intraprocedural FLIm has been implemented for biopsy guidance. Methods: A FLIm imaging system (fiber-optic probe; pulsed excitation: 355 nm; avalanche photodiode (APD)-based detection: 470/28 nm, 540/50 nm) linked to a stereotactic navigation platform was used to image tissue through the 10-mm side opening of a 1-mm-diameter needle during MRI-directed stereotactic biopsy of 5 suspected malignant gliomas. As the biopsy needle advanced to its targets, FLIm data were continuously acquired and displayed in real time. The data were analyzed by a classification model (trained with an independent dataset from 364 specimens from resection margins of 61 malignant gliomas), and displayed as the probability of the needle's tip lying within the targeted lesion. Predictions from FLIm were compared with biopsy histopathology. Results: Differences in FLIm-derived parameters (intensity, lifetime, Laguerre coefficient) permitted distinguishing lesion (biopsy-confirmed) from uninvolved brain (not biopsy-confirmed) with 81% accuracy and an area under the curve of 88%. Differentiation was better for oligodendroglioma and astrocytoma than for nonenhancing glioblastoma and necrosis. Conclusions: Incorporating FLIm with standard stereotactic biopsy needle and workflow could provide real-time guidance in selecting biopsy targets along the needle's trajectory, potentially improving diagnostic yield and safety. This approach may also aid biopsy of other body tissues and the placement of brain probes treating functional disorders.

Indexed as

fluorescence lifetime imaginglabel-free imagingstereotactic brain biopsysurgical guidance

Identifiers

PMID41104039
PMCPMC12527272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.